Recommended Medications for Psychogenic Erectile Dysfunction
For men with psychogenic erectile dysfunction, PDE5 inhibitors (sildenafil, vardenafil, tadalafil, or avanafil) are the first-line pharmacological treatment, combined with psychosocial interventions including cognitive behavioral therapy and sexual skills training 1.
Treatment Algorithm
First-Line: PDE5 Inhibitors + Psychotherapy
The 2025 EAU guidelines establish PDE5 inhibitors as the primary medical treatment for psychogenic ED 1. Selection among the four available agents depends on:
- Intercourse frequency patterns: Tadalafil's longer half-life suits men desiring spontaneity or frequent sexual activity
- Onset timing preferences: Avanafil and vardenafil offer faster onset
- Patient preference and tolerability
Critically, psychosocial interventions should be delivered concurrently with PDE5 inhibitors, not as an alternative 1. Sexual skills training and cognitive behavioral therapy—whether delivered individually or online—complement medical treatment effectively and address the underlying psychological factors.
Sildenafil has demonstrated significant efficacy specifically in psychogenic ED populations, with patients reporting improved erection frequency, hardness, duration, and overall sexual satisfaction compared to placebo 2.
For PDE5 Inhibitor Non-Responders
Before declaring treatment failure, verify:
- Proper dosing and timing: Many apparent non-responders are using medication incorrectly 1
- Adequate sexual stimulation: Education about the need for arousal can restore effectiveness 1
If true non-response occurs, consider:
- Switching PDE5 inhibitors: Though evidence is limited, different agents may work for individual patients 1
- Combination approaches:
- PDE5 inhibitors with antioxidants
- Low-intensity shockwave therapy (LI-SWT) combined with daily tadalafil 1
- Intracavernous injection therapy: Alprostadil or combination vasoactive drugs remain effective at any treatment stage 1, 3
Alternative and Adjunctive Pharmacological Options
Trazodone (Off-Label)
Trazodone may benefit men with psychogenic ED, particularly at higher doses (150-200 mg/day versus 50 mg/day) 4. However, the evidence is limited by small, brief, methodologically weak trials. Common adverse effects include dry mouth (19%), sedation (16%), dizziness (16%), and fatigue (15%) 4. This should be considered only when PDE5 inhibitors have failed or are contraindicated.
Cabergoline (Research Stage)
One randomized controlled trial showed cabergoline improved erectile function in psychogenic ED with normalization of hormone levels 5. However, this lacks guideline support and requires further validation before clinical recommendation.
Sublingual Apomorphine
This centrally-acting dopamine agonist works within 20 minutes by triggering hypothalamic erection centers 6. While it offers spontaneity advantages, it is not included in current major guidelines and has limited availability.
Critical Caveats
Common pitfall: Prescribing PDE5 inhibitors without addressing psychological factors leads to suboptimal outcomes. The psychogenic component requires concurrent psychological intervention 1.
Testosterone is NOT effective monotherapy for psychogenic ED unless documented hypogonadism exists 3. If testosterone deficiency is present, combination therapy (testosterone + PDE5 inhibitor) outperforms PDE5 inhibitors alone 3.
Avoid premature escalation to invasive treatments: Vacuum erection devices, intraurethral alprostadil, and intracavernous injections should be reserved for PDE5 inhibitor failures after proper education and dose optimization 1, 3.
Monitoring and Follow-Up
Reassess after 4-6 attempts with proper medication use. If inadequate response persists despite correct technique and adequate dosing, consider:
- Underlying organic factors that were initially missed
- Need for more intensive psychotherapy
- Relationship factors requiring couples counseling
- Progression to second-line therapies
The goal is restoration of satisfactory sexual function with minimal treatment burden, recognizing that psychogenic ED often requires addressing both biological and psychological dimensions simultaneously.